GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Enterprise Value

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Enterprise Value : $0.00 Mil (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VioQuest Pharmaceuticals's Enterprise Value is $0.00 Mil. VioQuest Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2008 was $-7.05 Mil. Therefore, VioQuest Pharmaceuticals's EV-to-EBIT ratio for today is 0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, VioQuest Pharmaceuticals's Enterprise Value is $0.00 Mil. VioQuest Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2008 was $-5.85 Mil. Therefore, VioQuest Pharmaceuticals's EV-to-EBITDA ratio for today is 0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, VioQuest Pharmaceuticals's Enterprise Value is $0.00 Mil. VioQuest Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2008 was $0.00 Mil. Therefore, VioQuest Pharmaceuticals's EV-to-Revenue ratio for today is .


VioQuest Pharmaceuticals Enterprise Value Historical Data

The historical data trend for VioQuest Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Enterprise Value Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.14 11.20 29.29 25.74 7.70

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.88 16.48 7.70 3.79 1.10

Competitive Comparison of VioQuest Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, VioQuest Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VioQuest Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's Enterprise Value falls into.



VioQuest Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

VioQuest Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2007 is calculated as

VioQuest Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2008 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals  (OTCPK:VOQP) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

VioQuest Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-7.05
=0.00

VioQuest Pharmaceuticals's current Enterprise Value is $0.00 Mil.
VioQuest Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.05 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

VioQuest Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.000/-5.845
=0.00

VioQuest Pharmaceuticals's current Enterprise Value is $0.00 Mil.
VioQuest Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.85 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

VioQuest Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/0
=

VioQuest Pharmaceuticals's current Enterprise Value is $0.00 Mil.
VioQuest Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines